Across five randomized controlled trials enrolling 2,204 overweight or obese Chinese adults, GLP-1 receptor agonists (including dual GLP-1/GIP agonists) produced a mean body weight reduction of 10.06 kg, waist circumference decrease of 7.06 cm, HbA1c drop of 0.41%, fasting glucose reduction of 0.48 mmol/L, cholesterol reduction of 7.95 mg/dL, and systolic blood pressure decline of 4.26 mmHg versus placebo. Gastrointestinal side effects—nausea, diarrhea, vomiting—were elevated, but serious adverse events were not.
The 10 kg weight reduction figure stands out as notably larger than effects observed in predominantly Western cohorts in landmark trials like STEP and SURMOUNT, though heterogeneity across only five trials (n=2,204) makes this estimate fragile. Chinese adults carry disproportionate metabolic risk at lower BMI thresholds, meaning these cardiometabolic improvements—particularly the blood pressure and glycemic reductions—may translate to outsized cardiovascular event reduction in this population. The cholesterol reduction of nearly 8 mg/dL, often underreported in GLP-1 literature, adds meaningful atherosclerotic risk mitigation beyond weight alone.
Critical limitations temper enthusiasm: only five trials with moderate pooled sample size, potential publication bias toward positive outcomes, and unclear breakdown between GLP-1 monotherapy versus dual GIP/GLP-1 agonists like tirzepatide, which confounds mechanism-specific conclusions. This meta-analysis is confirmatory in broad strokes but genuinely informative for Chinese-specific clinical guidelines, where population-tailored evidence has been scarce.